LIVIVO - Search results -

Search results

Result 1 - 10 of total 31

Search options

Article ; Online: Software to predict the right dose for vancomycin in a clinical environment-A commentary on: Personalised dosing of vancomycin: A prospective and retrospective comparative quasi-experimental study by Luqman Vali et al.

Dijkstra, Jacob A / Veldkamp, Agnes I / Sieswerda, Elske / van Agtmael, Michiel

British journal of clinical pharmacology

2021 Volume 87, Issue 9, Page(s) 3481–3482

MeSH term(s)	Anti-Bacterial Agents/adverse effects ; Humans ; Prospective Studies ; Retrospective Studies ; Software ; Vancomycin/adverse effects
Chemical Substances	Anti-Bacterial Agents ; Vancomycin (6Q205EH1VU)
Language	English
Publishing date	2021-02-27
Publishing country	England
Document type	Journal Article ; Comment
ZDB-ID	188974-6
ISSN	1365-2125 ; 0306-5251 ; 0264-3774
ISSN (online)	1365-2125
ISSN	0306-5251 ; 0264-3774
DOI	10.1111/bcp.14765
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1118: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Vitek

Sieswerda, Elske / Bosch, Thijs / Lankelma, Jacqueline M / Schouls, Leo M / Dijk, Karin van

Future microbiology

2021 Volume 16, Page(s) 777–781

Abstract: Aim: ...

Abstract	Aim:
MeSH term(s)	Anti-Bacterial Agents/pharmacology ; Bacterial Proteins ; Ciprofloxacin/pharmacology ; Imipenem/pharmacology ; Microbial Sensitivity Tests ; Pseudomonas aeruginosa/drug effects ; Pseudomonas aeruginosa/genetics ; Tobramycin/pharmacology ; beta-Lactamases
Chemical Substances	Anti-Bacterial Agents ; Bacterial Proteins ; Ciprofloxacin (5E8K9I0O4U) ; Imipenem (71OTZ9ZE0A) ; beta-Lactamases (EC 3.5.2.6) ; carbapenemase (EC 3.5.2.6) ; Tobramycin (VZ8RRZ51VK)
Language	English
Publishing date	2021-07-07
Publishing country	England
Document type	Journal Article
ZDB-ID	2254620-0
ISSN	1746-0921 ; 1746-0913
ISSN (online)	1746-0921
ISSN	1746-0913
DOI	10.2217/fmb-2020-0024
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: An Age Dependent Pharyngeal Microbiota Signature Associated with SARS-CoV-2 Infection

Budding, Andries / Sieswerda, Elske / Wintermans, Bastiaan / Bos, Martine

SSRN Electronic Journal ; ISSN 1556-5068

2020

Keywords	covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
DOI	10.2139/ssrn.3582780
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Guidance of empirical antimicrobial therapy by surveillance cultures in high-risk neutropenic patients: a retrospective cohort study.

de la Court, Jara R / Heijmans, Jarom / Huynh, Jennifer / Sieswerda, Elske / de Jonge, Nick A / van Dijk, Karin / Sigaloff, Kim C E / Schade, Rogier P

Antimicrobial resistance and infection control

2022 Volume 11, Issue 1, Page(s) 160

Abstract: Background: In neutropenic patients, bloodstream infections (BSI) significantly contribute to morbidity and mortality. Appropriate empirical antibiotic therapy (EAT) of BSI is essential, at the same time overconsumption of very broad-spectrum ... ...

Abstract	Background: In neutropenic patients, bloodstream infections (BSI) significantly contribute to morbidity and mortality. Appropriate empirical antibiotic therapy (EAT) of BSI is essential, at the same time overconsumption of very broad-spectrum antibiotics should be avoided. We investigated: (1) whether surveillance cultures can predict BSI with third-generation cephalosporin -resistant Enterobacterales and Pseudomonas aeruginosa (3GC-R), (2) the effect of inappropriate empirical antimicrobial therapy (IEAT) on clinical outcome and (3) the potential reduction of carbapenem use when using surveillance cultures to guide therapy. Methods: Retrospective study of adult patients with haematological malignancies with febrile episodes during chemotherapy-induced high-risk neutropenia in whom surveillance cultures were collected weekly. IEAT was defined as the absence of in vitro susceptibility of blood-isolates to the administered EAT. Clinical outcome (ICU admission and death) was evaluated within 30 days. Results: A total of 673 febrile episodes occurred among 372 high-risk neutropenic patients. BSI was present in 20.1% (135/673), of which 25.9% (35/135) were due to Enterobacterales and P. aeruginosa. Of these, 17/35 were 3GC-R and 70.6% (12/17) were preceded by 3GC-R colonization. Negative predictive value of surveillance cultures for 3GC-R BSI was 99.1%. IEAT due to (3GC-R) BSI was not significantly associated with clinical outcome. Using surveillance cultures to guide EAT could potentially reduce carbapenem use by 82.8%, when compared to standard EAT with carbapenem. Conclusions: This retrospective analysis shows that in patients with high-risk neutropenia, surveillance cultures can potentially reduce the use of carbapenems with infrequent IEAT for 3GC-R BSI and no negative impact on clinical outcome.
MeSH term(s)	Adult ; Humans ; Retrospective Studies ; Bacteremia/epidemiology ; Anti-Infective Agents/therapeutic use ; Neutropenia ; Carbapenems/therapeutic use ; Carbapenems/pharmacology ; Pseudomonas aeruginosa ; Sepsis/epidemiology
Chemical Substances	Anti-Infective Agents ; Carbapenems
Language	English
Publishing date	2022-12-18
Publishing country	England
Document type	Journal Article
ZDB-ID	2666706-X
ISSN	2047-2994 ; 2047-2994
ISSN (online)	2047-2994
ISSN	2047-2994
DOI	10.1186/s13756-022-01198-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam.

Sieswerda, Elske / van den Brand, Marre / van den Berg, Roland B / Sträter, Joris / Schouls, Leo / van Dijk, Karin / Budding, Andries E

The Journal of antimicrobial chemotherapy

2019 Volume 75, Issue 3, Page(s) 773–775

MeSH term(s)	Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/therapeutic use ; Aztreonam ; Ceftazidime ; Drug Combinations ; Humans ; Klebsiella Infections/drug therapy ; Klebsiella pneumoniae ; Microbial Sensitivity Tests ; Nebulizers and Vaporizers ; Powders ; Sepsis/drug therapy ; beta-Lactamases
Chemical Substances	Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; Powders ; avibactam (7352665165) ; Ceftazidime (9M416Z9QNR) ; beta-Lactamases (EC 3.5.2.6) ; Aztreonam (G2B4VE5GH8)
Language	English
Publishing date	2019-11-26
Publishing country	England
Document type	Letter
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkz495
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Using a BonE BiOPsy (BeBoP) to determine the causative agent in persons with diabetes and foot osteomyelitis: study protocol for a multicentre, randomised controlled trial.

Gramberg, Meryl Cinzía Tila Tamara / Lagrand, Rimke Sabine / Sabelis, Louise Willy Elizabeth / den Heijer, Martin / de Groot, Vincent / Nieuwdorp, Max / Kortmann, Willemijn / Sieswerda, Elske / Peters, Edgar Josephus Gerardus

Trials

2021 Volume 22, Issue 1, Page(s) 517

Abstract: Background: Diabetic foot osteomyelitis (DFO) poses a major disease burden. It can generally be treated with long-term antibacterial therapy. International guidelines recommend to base antibacterial therapy choices on percutaneous bone biopsy culture, ... ...

Abstract	Background: Diabetic foot osteomyelitis (DFO) poses a major disease burden. It can generally be treated with long-term antibacterial therapy. International guidelines recommend to base antibacterial therapy choices on percutaneous bone biopsy culture, while in practice, therapy is frequently based on (less invasive) ulcer bed cultures. It is currently unknown if treatment outcomes of DFO differ depending on the chosen diagnostic strategy. Methods: The BeBoP trial is a multicentre; randomised controlled; physician-, researcher- and subject-blinded; clinical trial comparing two diagnostic strategies in persons with DFO. Culture-directed antibacterial therapy will be based on either percutaneous bone biopsy culture results (intervention group) or ulcer bed biopsy culture results (comparison group). We will enrol 80 subjects with diabetes mellitus (≥ 18 years) and DFO, and we will use block randomisation stratified per centre to randomise them in a 1:1 allocation. The primary outcome is remission of DFO 12 months after enrolment. The secondary outcomes are the time to remission, signs of inflammation or ulceration at the primary location of infection at 6 and 12 months, microbiological and molecular profiles of culture outcomes, surgical interventions including amputation, total antibacterial therapy duration, infection-free survival days, adverse events, quality of life and survival. We will compare the outcomes by intention-to-treat and per-protocol analysis. Discussion: We aim to compare clinical remission in persons with DFO treated with antibacterial therapy based on either percutaneous bone biopsy culture results or ulcer bed biopsy culture results. Trial registration: Netherlands Trial Register NL 7582 . Registered on 05 March 2019.
MeSH term(s)	Biopsy ; Diabetes Mellitus ; Diabetic Foot/diagnosis ; Diabetic Foot/drug therapy ; Humans ; Multicenter Studies as Topic ; Netherlands ; Osteomyelitis/diagnosis ; Osteomyelitis/drug therapy ; Quality of Life ; Randomized Controlled Trials as Topic
Language	English
Publishing date	2021-08-03
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article
ZDB-ID	2040523-6
ISSN	1745-6215 ; 1468-6694 ; 1468-6708
ISSN (online)	1745-6215 ; 1468-6694
ISSN	1468-6708
DOI	10.1186/s13063-021-05472-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Antibiotic Therapy of 3 Days May Be Sufficient After Biliary Drainage for Acute Cholangitis: A Systematic Review.

Haal, Sylke / Wielenga, Mattheus C B / Fockens, Paul / Leseman, Charlotte A / Ponsioen, Cyriel Y / van Soest, Ellert J / van Wanrooij, Roy L J / Sieswerda, Elske / Voermans, Rogier P

Digestive diseases and sciences

2021 Volume 66, Issue 12, Page(s) 4128–4139

Abstract: Background: The optimal antibiotic therapy duration for cholangitis is unclear. Guideline recommendations vary between 4 and 14 days after biliary drainage. Clinical observations and some evidence however suggest that shorter antibiotic therapy may be ... ...

Abstract	Background: The optimal antibiotic therapy duration for cholangitis is unclear. Guideline recommendations vary between 4 and 14 days after biliary drainage. Clinical observations and some evidence however suggest that shorter antibiotic therapy may be sufficient. Objective: To compare the effectiveness and safety of short-course therapy of ≤ 3 days with long-course therapy of ≥ 4 days after biliary drainage in cholangitis patients. Methods: We searched the databases PubMed, EMBASE, Cochrane Library, and trial registers for literature up to August 5, 2020. RCTs and observational studies including case series reporting on antibiotic therapy duration for acute cholangitis were eligible for inclusion. Two reviewers independently evaluated study eligibility, extracted data, assessed risk of bias and quality of evidence. A meta-analysis was planned if the included studies were comparable with regard to important study characteristics. Primary outcomes included recurrent cholangitis, subsequent other infection, and mortality. Results: We included eight studies with 938 cholangitis patients. Four observational studies enrolled patients treated for ≤ 3 days. Recurrent cholangitis occurred in 0-26.8% of patients treated with short-course therapy, which did not differ from long-course therapy (range 0-21.1%). Subsequent other infection and mortality rates were also comparable. Quality of available evidence was very low. Conclusion: There is no high-quality evidence available to draw a strong conclusion, but heterogeneous observational studies suggest that antibiotic therapy of ≤ 3 days is sufficient in cholangitis patients with common bile duct stones.
MeSH term(s)	Acute Disease ; Anti-Bacterial Agents/administration & dosage ; Anti-Bacterial Agents/adverse effects ; Antibiotic Prophylaxis/adverse effects ; Cholangitis/diagnosis ; Cholangitis/therapy ; Drainage/adverse effects ; Drug Administration Schedule ; Evidence-Based Medicine ; Humans ; Time Factors ; Treatment Outcome
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2021-01-19
Publishing country	United States
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	304250-9
ISSN	1573-2568 ; 0163-2116
ISSN (online)	1573-2568
ISSN	0163-2116
DOI	10.1007/s10620-020-06820-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui V Zs.35: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Using a BonE BiOPsy (BeBoP) to determine the causative agent in persons with diabetes and foot osteomyelitis

Meryl Cinzía Tila Tamara Gramberg / Rimke Sabine Lagrand / Louise Willy Elizabeth Sabelis / Martin den Heijer / Vincent de Groot / Max Nieuwdorp / Willemijn Kortmann / Elske Sieswerda / Edgar Josephus Gerardus Peters

Trials, Vol 22, Iss 1, Pp 1-

study protocol for a multicentre, randomised controlled trial

2021 Volume 10

Abstract: Abstract Background Diabetic foot osteomyelitis (DFO) poses a major disease burden. It can generally be treated with long-term antibacterial therapy. International guidelines recommend to base antibacterial therapy choices on percutaneous bone biopsy ... ...

Abstract	Abstract Background Diabetic foot osteomyelitis (DFO) poses a major disease burden. It can generally be treated with long-term antibacterial therapy. International guidelines recommend to base antibacterial therapy choices on percutaneous bone biopsy culture, while in practice, therapy is frequently based on (less invasive) ulcer bed cultures. It is currently unknown if treatment outcomes of DFO differ depending on the chosen diagnostic strategy. Methods The BeBoP trial is a multicentre; randomised controlled; physician-, researcher- and subject-blinded; clinical trial comparing two diagnostic strategies in persons with DFO. Culture-directed antibacterial therapy will be based on either percutaneous bone biopsy culture results (intervention group) or ulcer bed biopsy culture results (comparison group). We will enrol 80 subjects with diabetes mellitus (≥ 18 years) and DFO, and we will use block randomisation stratified per centre to randomise them in a 1:1 allocation. The primary outcome is remission of DFO 12 months after enrolment. The secondary outcomes are the time to remission, signs of inflammation or ulceration at the primary location of infection at 6 and 12 months, microbiological and molecular profiles of culture outcomes, surgical interventions including amputation, total antibacterial therapy duration, infection-free survival days, adverse events, quality of life and survival. We will compare the outcomes by intention-to-treat and per-protocol analysis. Discussion We aim to compare clinical remission in persons with DFO treated with antibacterial therapy based on either percutaneous bone biopsy culture results or ulcer bed biopsy culture results. Trial registration Netherlands Trial Register NL 7582 . Registered on 05 March 2019
Keywords	Osteomyelitis in diabetic foot ; Bone biopsy ; Antibacterial therapy ; Medicine (General) ; R5-920
Subject code	616
Language	English
Publishing date	2021-08-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults.

Sieswerda, Elske / Bax, Hannelore I / Hoogerwerf, Jacobien J / de Boer, Mark G J / Boermeester, Marja / Bonten, Marc J M / Dekker, Douwe / van Wijk, Roy Gerth / Juffermans, Nicole P / Kuindersma, Marnix / van der Linden, Paul D / Melles, Damian C / Pickkers, Peter / Schouten, Jeroen A / Rebel, Jasper R / van Zanten, Arthur R H / Prins, Jan M / Wiersinga, W Joost

BMC infectious diseases

2022 Volume 22, Issue 1, Page(s) 687

Abstract: Background: The Dutch Working Party on Antibiotic Policy (SWAB) in collaboration with relevant professional societies, has updated their evidence-based guidelines on empiric antibacterial therapy of sepsis in adults.: Methods: Our multidisciplinary ... ...

Abstract	Background: The Dutch Working Party on Antibiotic Policy (SWAB) in collaboration with relevant professional societies, has updated their evidence-based guidelines on empiric antibacterial therapy of sepsis in adults. Methods: Our multidisciplinary guideline committee generated ten population, intervention, comparison, and outcome (PICO) questions relevant for adult patients with sepsis. For each question, a literature search was performed to obtain the best available evidence and assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. The quality of evidence for clinically relevant outcomes was graded from high to very low. In structured consensus meetings, the committee formulated recommendations as strong or weak. When evidence could not be obtained, recommendations were provided based on expert opinion and experience (good practice statements). Results: Fifty-five recommendations on the antibacterial therapy of sepsis were generated. Recommendations on empiric antibacterial therapy choices were differentiated for sepsis according to the source of infection, the potential causative pathogen and its resistance pattern. One important revision was the distinction between low, increased and high risk of infection with Enterobacterales resistant to third generation cephalosporins (3GRC-E) to guide the choice of empirical therapy. Other new topics included empirical antibacterial therapy in patients with a reported penicillin allergy and the role of pharmacokinetics and pharmacodynamics to guide dosing in sepsis. We also established recommendations on timing and duration of antibacterial treatment. Conclusions: Our multidisciplinary committee formulated evidence-based recommendations for the empiric antibacterial therapy of adults with sepsis in The Netherlands.
MeSH term(s)	Adult ; Anti-Bacterial Agents/therapeutic use ; Humans ; Netherlands ; Policy ; Sepsis/drug therapy
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2022-08-11
Publishing country	England
Document type	Journal Article
ZDB-ID	2041550-3
ISSN	1471-2334 ; 1471-2334
ISSN (online)	1471-2334
ISSN	1471-2334
DOI	10.1186/s12879-022-07653-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Low frequency of community-acquired bacterial co-infection in patients hospitalized for COVID-19 based on clinical, radiological and microbiological criteria: a retrospective cohort study.

Coenen, Sophie / de la Court, Jara R / Buis, David T P / Meijboom, Lilian J / Schade, Rogier P / Visser, Caroline E / van Hest, Reinier / Kuijvenhoven, Marianne / Prins, Jan M / Nijman, Suzan F M / Sieswerda, Elske / Sigaloff, Kim C E

Antimicrobial resistance and infection control

2021 Volume 10, Issue 1, Page(s) 155

Abstract: Background: We defined the frequency of respiratory community-acquired bacterial co-infection in patients with COVID-19, i.e. patients with a positive SARS-CoV-2 PCR or a COVID-19 Reporting and Data System (CO-RADS) score ≥ 4, based on a complete ... ...

Abstract	Background: We defined the frequency of respiratory community-acquired bacterial co-infection in patients with COVID-19, i.e. patients with a positive SARS-CoV-2 PCR or a COVID-19 Reporting and Data System (CO-RADS) score ≥ 4, based on a complete clinical assessment, including prior antibiotic use, clinical characteristics, inflammatory markers, chest computed tomography (CT) results and microbiological test results. Methods: Our retrospective study was conducted within a cohort of prospectively included patients admitted for COVID-19 in our tertiary medical centres between 1-3-2020 and 1-6-2020. A multidisciplinary study team developed a diagnostic protocol to retrospectively categorize patients as unlikely, possible or probable bacterial co-infection based on clinical, radiological and microbiological parameters in the first 72 h of admission. Within the three categories, we summarized patient characteristics and antibiotic consumption. Results: Among 281 included COVID-19 patients, bacterial co-infection was classified as unlikely in 233 patients (82.9%), possible in 35 patients (12.4%) and probable in 3 patients (1.1%). Ten patients (3.6%) could not be classified due to inconclusive data. Within 72 h of hospital admission, 81% of the total study population and 78% of patients classified as unlikely bacterial co-infection received antibiotics. Conclusions: COVID-19 patients are unlikely to have a respiratory community-acquired bacterial co-infection. This study underpins recommendations for restrictive use of antibacterial drugs in patients with COVID-19.
MeSH term(s)	Adult ; Anti-Bacterial Agents/therapeutic use ; Antimicrobial Stewardship ; Bacterial Infections/drug therapy ; Bacterial Infections/epidemiology ; Bacterial Infections/microbiology ; COVID-19/complications ; COVID-19/diagnosis ; Cohort Studies ; Coinfection/drug therapy ; Coinfection/epidemiology ; Community-Acquired Infections/epidemiology ; Community-Acquired Infections/microbiology ; Female ; Hospitalization/statistics & numerical data ; Humans ; Male ; Middle Aged ; Pneumonia/epidemiology ; Retrospective Studies ; SARS-CoV-2
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2021-10-30
Publishing country	England
Document type	Journal Article
ZDB-ID	2666706-X
ISSN	2047-2994 ; 2047-2994
ISSN (online)	2047-2994
ISSN	2047-2994
DOI	10.1186/s13756-021-01024-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito